Biologics Contract Manufacturing Market (2024 - 2034)
Biologics Contract Manufacturing Market Study by Monoclonal Antibodies, Recombinant Proteins, Insulin, Vaccines, Interferons, and Growth Factors from 2024 to 2034
Core Findings
Biologics Contract Manufacturing Market Outlook (2024 to 2034)
The global biologics contract manufacturing market size is estimated at US$ 21.19 billion in 2024, as per a new Fact.MR industry report. Worldwide demand for biologics contract manufacturing is predicted to rise at a noteworthy 9.4% CAGR and reach a market value of US$ 51.81 billion by the end of 2034.
Increasing cases of chronic diseases along with a shift to personalized medicines is predicted to contribute to the rising demand for biologic drugs, which is subsequently generating the need for contract manufacturing services.
Constant technological advancements taking place in biotechnology, especially in fields such as cell culture technologies, protein expression systems, and genetic engineering, are predicted to increase the complexity of biological drug manufacturing and expand their scope of application, thus stimulating the need for specialized manufacturing expertise.
Majority of biopharmaceutical companies generally opt for contract manufacturing to minimize capital investment in infrastructure. Furthermore, they are placing a strong emphasis on expanding their manufacturing facilities to increase their production capacity.
Stringent regulations governing biopharmaceutical manufacturing are predicted to increase these companies’ dependency on contract manufacturing organizations (CMOs) with expertise in regulatory compliance, thus ensuring adherence to safety protocols and quality standards.
- Demand for biologics contract manufacturing services in North America is predicted to accelerate at 9.5% CAGR and reach a value of US$ 2.58 billion by 2034-end.
- The commercial segment is predicted to account for 73.8% of biologics contract manufacturing market share by 2034.
- Revenue from biologics contract manufacturing services in oncology is projected to increase at a CAGR of 8.3% and reach US$ 12.30 billion by 2034-end.
Strategic collaborations between biologics contract manufacturing and biopharma companies are projected to contribute to market expansion while combining capabilities, resources, and expertise. Biologics contract manufacturing services are projected to be in high demand due to the increased need for prompt vaccine development and improved manufacturing capabilities. This is primarily due to their cost-effectiveness when compared to original biologics.
| Report Attributes | Details |
|---|---|
| Biologics Contract Manufacturing Market Size (2024E) | US$ 21.19 Billion |
| Forecasted Market Value (2034F) | US$ 51.81 Billion |
| Global Market Growth Rate (2024 to 2034) | 9.4% CAGR |
| Canada Market Growth Rate (2024 to 2034F) | 8.2% CAGR |
| East Asia Market Share (2034F) | 5.3% |
| Monoclonal Antibodies Segment Growth Rate (2024 to 2034) | 8.3% CAGR |
| Oncology Segment Market Share (2034F) | 23.8% |
| Key Companies Profiled | Lonza Group AG; BioXcellence; Samsung Biologics; AbbVie CM; Fujifilm Diosynth Biotechnologies; AGC Biologics; Patheon N.V.; Ajinomoto Bio-Pharma; Emergent BioSolutions Inc.; Avid Bioservices, Inc.; Rentschler Biotechnologies GmbH; KBI Biopharma; Merck KGaA; Novasep; Therapure Biopharma Inc.; Abzena Plc.; ProBioGen AG |
What is Responsible for High Demand for Biologics Contract Manufacturing?
“Focus on Outsourcing R&D Activities to Minimize Operation Costs”
The biopharmaceutical CMO sector is expected to grow and undergo consolidation as companies pursue strategies to offer integrated solutions to their customers. Ongoing scientific advancements in biopharmaceuticals are predicted to create opportunities for players with high potential.
For instance :
- AGC Biologics, in July 2020, completed the acquisition of Molecular Medicine S.p.A. to add to its capabilities in gene therapy and plasmid production services. The company’s revenue stream is expected to be impacted by the presence of companies with advanced biologic and biosimilar manufacturing facilities.
Focus on minimizing operation costs through the commercialization of biopharmaceuticals and outsourcing of R&D activities for product innovations is predicted to enhance operational effectiveness. In addition, outsourcing at the later stages of clinical development with the assistance of appointment and identification of a strategic partner is predicted to improve the effectiveness of the value chain.
The emerging model of CDMO business, disruptive drug development, transformation taking place in the pharmaceutical ecosystem, and expansion of biopharmaceutical manufacturing are predicted to drive growth opportunities in the market over the next decade.
Which Factors Can Adversely Impact Market Growth Going Forward?
“Changing Regulatory Framework Resulting in Increased Cost of Products”
Regulatory policies along with stringent inspection regimes are predicted to cause issues in the security of the supply chain across several emerging countries and are projected to have adverse effects on the prices of end products. Start-ups trying to enter this space face financial challenges due to the abovementioned factors, therefore making their entry an expensive affair.
“Dearth of Skilled Manpower Hampering Global Market Growth”
The contribution of skilled professionals is vital for economic development in emerging regions. Reports from various companies indicate a notable gap in the workforce between the number of available skilled professionals and the increasing demand in specific industries. Poor planning, shortage of skilled individuals, and inadequate funding are forecasted to hamper market growth.
What Initiatives are Start-ups Taking to Secure Their Market Position?
“Focus on Process Improvements and Technological Innovations”
Continuous innovations taking place in manufacturing technologies, including improved analytics, process automation, and single-use systems, are forecasted to lead to enhanced yield and productivity, which is further contributing to the biologics contract manufacturing market growth. Furthermore, the cost-efficiency of these newly developed systems is also predicted to help new entrants get a competitive edge.
Country-wise Insights
Demand for biologics contract manufacturing services in North America is projected to advance at a CAGR of 9.5% and reach a value of US$ 2.58 billion by the end of 2034. The presence of several key players and their involvement in the production of high-quality and cost-efficient solutions is forecasted to contribute to the expansion of the biologics contract manufacturing market size.
Why is Demand for Biologics Contract Manufacturing Services High in the United States?
“Well-Established Biological Pipelines and Heavy Investments in Healthcare”
| Attribute | United States |
|---|---|
| Market Value (2024E) | US$ 931.8 Million |
| Growth Rate (2024 to 2034) | 9.6% CAGR |
| Projected Value (2034F) | US$ 2.34 Billion |
The United States is forecasted to account for 90.6% share of the market in North America by 2034. The nation boasts well-established biological pipelines and increased capital investments, which is fueling demand for biologics contract manufacturing. In addition, the establishment of many research institutions and the presence of manufacturers with specialized methodologies are contributing to market expansion.
Why are Biologics Contract Manufacturing Service Providers Eyeing China?
“Growing Collaborations between Industry Players and Local Manufacturing Organizations”
| Attribute | China |
|---|---|
| Market Value (2024E) | US$ 763.3 Million |
| Growth Rate (2024 to 2034) | 10.1% CAGR |
| Projected Value (2034F) | US$ 2 Billion |
China is predicted to hold 72.4% share of the East Asia market by 2034. Several biopharma and pharma companies are focusing on capitalizing on their growth by looking for opportunities to collaborate with various local organizations to establish themselves.
Category-wise Insights
Fact.MR, a market research and competitive intelligence provider, in its newly published study, asserts that the demand for monoclonal antibodies is predicted to increase further owing to their increased use in treatments for chronic Hepatitis B (HBV) infection, cancer, autoimmune diseases, and infectious diseases.
Why Do Monoclonal Antibodies Account for Higher Demand?
“Rising Traction for Antibody Therapeutics in Biopharmaceuticals”
| Attribute | Monoclonal Antibodies |
|---|---|
| Segment Value (2024E) | US$ 8.9 Billion |
| Growth Rate (2024 to 2034) | 8.3% CAGR |
| Projected Value (2034F) | US$ 19.8 Billion |
Monoclonal antibodies are predicted to account for 38.2% share of the global market by 2034. The favorable safety profile and excellent specificity of monoclonal antibodies contribute to their increased use in biologics for the manufacturing of biopharmaceuticals. Biologics contract manufacturing market trends are expected to be driven by the increasing demand for various antibody-based treatments.
Which Platform is Projected to Gain Prominence among End Users?
“Enhanced Efficiency and Speed of Mammalian-Based Processes”
| Attribute | Mammalian |
|---|---|
| Segment Value (2024E) | US$ 15.55 Billion |
| Growth Rate (2024 to 2034) | 9.7% CAGR |
| Projected Value (2034F) | US$ 39.27 Billion |
The mammalian category is projected to hold 75.8% share of global market revenue by 2034. With reduced completion time and enhanced efficiency in mammalian-based processes, the platform is expected to gain more traction. Mammalian cell cultures, such as CHO cells, are projected to be preferred for biopharmaceutical manufacturing over other similar platforms.
What’s Contributing to Rising Demand for Biologics Contract Manufacturing in Oncology?
“Increasing Research Activities in Clinical Settings to Discover Novel Therapeutic Options”
| Attribute | Oncology |
|---|---|
| Segment Value (2024E) | US$ 5.56 Billion |
| Growth Rate (2024 to 2034) | 8.3% CAGR |
| Projected Value (2034F) | US$ 12.3 Billion |
The oncology segment is predicted to account for 23.8% share of the global market by 2034. The rising prevalence of oncologic conditions such as cancer is expected to drive demand for biologics contract manufacturing in this domain. Moreover, the entry of multiple manufacturers with innovative product lines and the increasing research activities in clinical settings to discover novel therapeutic options are poised to further fuel market expansion.
Which End-use Segment is Projected to Hold a Leading Market Share?
“Commercial Segment Accounts for Leading Market Share Due to Focus on Facility Expansion”
| Attribute | Commercial Sector |
|---|---|
| Segment Value (2024E) | US$ 15.26 Billion |
| Growth Rate (2024 to 2034) | 9.6% CAGR |
| Projected Value (2034F) | US$ 38.24 Billion |
The commercial segment is forecasted to account for 73.8% share of global market revenue by 2034. Growing need for biologic medications and scaling up of contract manufacturing facilities is projected to contribute to revenue streams in the commercial segment in the coming 10 years.
Competitive Landscape
Prominent companies in the market focus on the distribution network across the globe to generate revenue streams. They are also investing in the management of supply chain systems, new developments, product quality, etc.
For instance :
- Abzena Limited, in November 2021, established a collaboration with BiVictriX Therapeutics Plc. for the manufacturing of BiVictriX’s ADC (antibody-drug conjugates).
Key players in the biologics contract manufacturing market are Lonza Group AG, BioXcellence, Samsung Biologics, AbbVie CM, Fujifilm Diosynth Biotechnologies, AGC Biologics, Patheon N.V., Ajinomoto Bio-Pharma, Emergent BioSolutions Inc., Avid Bioservices, Inc., Rentschler Biotechnologies GmbH, KBI Biopharma, Merck KGaA, Novasep, Therapure Biopharma Inc., Abzena Plc., and ProBioGen AG.
Segmentation of Biologics Contract Manufacturing Market Research
-
By Product:
- Monoclonal Antibodies
- Recombinant Proteins
- Insulin
- Vaccines
- Interferons
- Growth Factors
- Others
-
By Platform:
- Mammalian
- Microbial
-
By Therapeutic Area:
- Oncology
- Metabolic Diseases
- Autoimmune Diseases
- Ophthalmology
- Infectious Diseases
- Cardiovascular Diseases
- Neurology
- Respiratory Disorders
- Others
-
By Application:
- Commercial
- Clinical
-
By Region:
- North America
- Europe
- East Asia
- Latin America
- Middle East & Africa
- South Asia & Oceania
Table of Content
- 1. Executive Summary
- 2. Market Overview
- 3. Market Background
- 4. Global Market Pricing Analysis
- 5. Global Market Analysis (2018 to 2023) and Forecast (2024 to 2034)
- 6. Global Market Analysis (2018 to 2023) and Forecast (2024 to 2034), by Product
- 6.1. Monoclonal Antibodies
- 6.2. Recombinant Proteins
- 6.3. Insulin
- 6.4. Vaccines
- 6.5. Interferons
- 6.6. Growth Factors
- 6.7. Others
- 7. Global Market Analysis (2018 to 2023) and Forecast (2024 to 2034), by Platform
- 7.1. Mammalian
- 7.2. Microbial
- 8. Global Market Analysis (2018 to 2023) and Forecast (2024 to 2034), by Application
- 8.1. Commercial
- 8.2. Clinical
- 9. Global Market Analysis (2018 to 2023) and Forecast (2024 to 2034), by Therapeutic Area
- 9.1. Oncology
- 9.2. Metabolic Diseases
- 9.3. Autoimmune Diseases
- 9.4. Ophthalmology
- 9.5. Infectious Diseases
- 9.6. Cardiovascular Diseases
- 9.7. Neurology
- 9.8. Respiratory Disorders
- 9.9. Others
- 10. Global Market Analysis (2018 to 2023) and Forecast (2024 to 2034), by Region
- 10.1. North America
- 10.2. Europe
- 10.3. East Asia
- 10.4. South Asia
- 10.5. Latin America
- 10.6. Middle East & Africa (MEA)
- 10.7. Oceania
- 11. North America Market Analysis and Forecast
- 12. Europe Market Analysis and Forecast
- 13. East Asia Market Analysis and Forecast
- 14. South Asia Market Analysis and Forecast
- 15. Latin America Market Analysis and Forecast
- 16. Middle East & Africa Market Analysis and Forecast
- 17. Oceania Market Analysis and Forecast
- 18. Global Market Analysis Key Countries
- 19. Competition Landscape
- 20. Competition Analysis
- 20.1. Lonza Group AG
- 20.2. BioXcellence
- 20.3. Samsung Biologics
- 20.4. AbbVie CM
- 20.5. Fujifilm Diosynth Biotechnologies
- 20.6. AGC Biologics
- 20.7. Patheon N.V.
- 20.8. Ajinomoto Bio-Pharma
- 20.9. Emergent BioSolutions Inc.
- 20.10. Avid Bioservices, Inc.
- 20.11. Rentschler Biotechnologies GmbH
- 20.12. KBI Biopharma
- 20.13. Merck KGaA
- 20.14. Novasep
- 20.15. Therapure Biopharma Inc.
- 20.16. Abzena Plc.
- 20.17. ProBioGen AG
- 21. Appendix
- 22. Definitions of Analytical Frameworks
- 23. Sources and References
List Of Table
Table 01: Global Market by Product, 2018 to 2034
Table 02: Global Market Value (US$ Mn), by Product, 2018 to 2034
Table 03: Global Market by Platform, 2018 to 2034
Table 04: Global Market Value (US$ Mn), by Platform, 2018 to 2034
Table 05: Global Market by Application, 2018 to 2034
Table 06: Global Market Value (US$ Mn), by Application, 2018 to 2034
Table 07: Global Market by Therapeutic Area, 2018 to 2034
Table 08: Global Market Value (US$ Mn), by Therapeutic Area, 2018 to 2034
Table 09: Global Market by Region, 2018 to 2034
Table 10: Global Market Value (US$ Mn), by Region, 2018 to 2034
Table 11: North America Market by Product, 2018 to 2034
Table 12: North America Market Value (US$ Mn), by Product, 2018 to 2034
Table 13: North America Market by Platform, 2018 to 2034
Table 14: North America Market Value (US$ Mn), by Platform, 2018 to 2034
Table 15: North America Market by Application, 2018 to 2034
Table 16: North America Market Value (US$ Mn), by Application, 2018 to 2034
Table 17: North America Market by Therapeutic Area, 2018 to 2034
Table 18: North America Market Value (US$ Mn), by Therapeutic Area, 2018 to 2034
Table 19: North America Market by Country, 2018 to 2034
Table 20: North America Market Value (US$ Mn), by Country, 2018 to 2034
Table 21: Europe Market by Product, 2018 to 2034
Table 22: Europe Market Value (US$ Mn), by Product, 2018 to 2034
Table 23: Europe Market by Platform, 2018 to 2034
Table 24: Europe Market Value (US$ Mn), by Platform, 2018 to 2034
Table 25: Europe Market by Application, 2018 to 2034
Table 26: Europe Market Value (US$ Mn), by Application, 2018 to 2034
Table 27: Europe Market by Therapeutic Area, 2018 to 2034
Table 28: Europe Market Value (US$ Mn), by Therapeutic Area, 2018 to 2034
Table 29: Europe Market by Country, 2018 to 2034
Table 30: Europe Market Value (US$ Mn), by Country, 2018 to 2034
Table 31: East Asia Market by Product, 2018 to 2034
Table 32: East Asia Market Value (US$ Mn), by Product, 2018 to 2034
Table 33: East Asia Market by Platform, 2018 to 2034
Table 34: East Asia Market Value (US$ Mn), by Platform, 2018 to 2034
Table 35: East Asia Market by Application, 2018 to 2034
Table 36: East Asia Market Value (US$ Mn), by Application, 2018 to 2034
Table 37: East Asia Market by Therapeutic Area, 2018 to 2034
Table 38: East Asia Market Value (US$ Mn), by Therapeutic Area, 2018 to 2034
Table 39: East Asia Market by Country, 2018 to 2034
Table 40: East Asia Market Value (US$ Mn), by Country, 2018 to 2034
Table 41: South Asia Market by Product, 2018 to 2034
Table 42: South Asia Market Value (US$ Mn), by Product, 2018 to 2034
Table 43: South Asia Market by Platform, 2018 to 2034
Table 44: South Asia Market Value (US$ Mn), by Platform, 2018 to 2034
Table 45: South Asia Market by Application, 2018 to 2034
Table 46: South Asia Market Value (US$ Mn), by Application, 2018 to 2034
Table 47: South Asia Market by Therapeutic Area, 2018 to 2034
Table 48: South Asia Market Value (US$ Mn), by Therapeutic Area, 2018 to 2034
Table 49: South Asia Market by Country, 2018 to 2034
Table 50: South Asia Market Value (US$ Mn), by Country, 2018 to 2034
Table 51: Latin America Market by Product, 2018 to 2034
Table 52: Latin America Market Value (US$ Mn), by Product, 2018 to 2034
Table 53: Latin America Market by Platform, 2018 to 2034
Table 54: Latin America Market Value (US$ Mn), by Platform, 2018 to 2034
Table 55: Latin America Market by Application, 2018 to 2034
Table 56: Latin America Market Value (US$ Mn), by Application, 2018 to 2034
Table 57: Latin America Market by Therapeutic Area, 2018 to 2034
Table 58: Latin America Market Value (US$ Mn), by Therapeutic Area, 2018 to 2034
Table 59: Latin America Market by Country, 2018 to 2034
Table 60: Latin America Market Value (US$ Mn), by Country, 2018 to 2034
Table 61: Middle East and Africa Market by Product, 2018 to 2034
Table 62: Middle East and Africa Market Value (US$ Mn), by Product, 2018 to 2034
Table 63: Middle East and Africa Market by Platform, 2018 to 2034
Table 64: Middle East and Africa Market Value (US$ Mn), by Platform, 2018 to 2034
Table 65: Middle East and Africa Market by Application, 2018 to 2034
Table 66: Middle East and Africa Market Value (US$ Mn), by Application, 2018 to 2034
Table 67: Middle East and Africa Market by Therapeutic Area, 2018 to 2034
Table 68: Middle East and Africa Market Value (US$ Mn), by Therapeutic Area, 2018 to 2034
Table 69: Middle East and Africa Market by Country, 2018 to 2034
Table 70: Middle East and Africa Market Value (US$ Mn), by Country, 2018 to 2034
Table 71: Oceania Market by Product, 2018 to 2034
Table 72: Oceania Market Value (US$ Mn), by Product, 2018 to 2034
Table 73: Oceania Market by Platform, 2018 to 2034
Table 74: Oceania Market Value (US$ Mn), by Platform, 2018 to 2034
Table 75: Oceania Market by Application, 2018 to 2034
Table 76: Oceania Market Value (US$ Mn), by Application, 2018 to 2034
Table 77: Oceania Market by Therapeutic Area, 2018 to 2034
Table 78: Oceania Market Value (US$ Mn), by Therapeutic Area, 2018 to 2034
Table 79: Oceania Market by Country, 2018 to 2034
Table 80: Oceania Market Value (US$ Mn), by Country, 2018 to 2034
List Of Figures
Fig 01: Global Market Value (US$) and Y-o-Y Growth, 2018 to 2034
Fig 02: Global Absolute $ Historical Market (2018 to 2023) and Absolute $ Opportunity (2024 to 2034), US$ Mn
Fig 03: Global Market Value Y-o-Y Growth and Forecast, 2018 to 2034
Fig 04: Global Market Incremental $ Opportunity (US$ Thousand), 2024 to 2034
Fig 05: Global Market Share, By Product - 2024 to 2034
Fig 06: Global Market Y-o-Y Growth Projections, By Product - 2024 to 2034
Fig 07: Global Market Attractiveness Index, By Product - 2024 to 2034
Fig 08: Global Market Share, By Platform - 2024 to 2034
Fig 09: Global Market Y-o-Y Growth Projections, By Platform - 2024 to 2034
Fig 10: Global Market Attractiveness Index, By Platform - 2024 to 2034
Fig 11: Global Market Share, By Application - 2024 to 2034
Fig 12: Global Market Y-o-Y Growth Projections, By Application - 2024 to 2034
Fig 13: Global Market Attractiveness Index, By Application - 2024 to 2034
Fig 14: Global Market Share, By Therapeutic Area - 2024 to 2034
Fig 15: Global Market Y-o-Y Growth Projections, By Therapeutic Area - 2024 to 2034
Fig 16: Global Market Attractiveness Index, By Therapeutic Area - 2024 to 2034
Fig 17: Global Market Share, by Region - 2024 to 2034
Fig 18: Global Market Y-o-Y Growth Projections, by Region - 2024 to 2034
Fig 19: Global Market Attractiveness Index, by Region - 2024 to 2034
Fig 20: Y-o-Y Growth Comparison of Market: North America Vs North America Countries Vs North America Average
Fig 21: North America Market Share, By Product - 2024 to 2034
Fig 22: North America Market Y-o-Y Growth Projections, By Product - 2024 to 2034
Fig 23: North America Market Attractiveness Index, By Product - 2024 to 2034
Fig 24: North America Market Share, By Platform - 2024 to 2034
Fig 25: North America Market Y-o-Y Growth Projections, By Platform - 2024 to 2034
Fig 26: North America Market Attractiveness Index, By Platform - 2024 to 2034
Fig 27: North America Market Share, By Application - 2024 to 2034
Fig 28: North America Market Y-o-Y Growth Projections, By Application - 2024 to 2034
Fig 29: North America Market Attractiveness Index, By Application - 2024 to 2034
Fig 30: North America Market Share, By Therapeutic Area - 2024 to 2034
Fig 31: North America Market Y-o-Y Growth Projections, By Therapeutic Area - 2024 to 2034
Fig 32: North America Market Attractiveness Index, By Therapeutic Area - 2024 to 2034
Fig 33: North America Market Share, By Country - 2024 to 2034
Fig 34: North America Market Y-o-Y Growth Projections, By Country - 2024 to 2034
Fig 35: North America Market Attractiveness Index, By Country - 2024 to 2034
Fig 36: Y-o-Y Growth Comparison of Market: Europe Vs Europe Countries Vs Europe Average
Fig 37: Europe Market Share, By Product - 2024 to 2034
Fig 38: Europe Market Y-o-Y Growth Projections, By Product - 2024 to 2034
Fig 39: Europe Market Attractiveness Index, By Product - 2024 to 2034
Fig 40: Europe Market Share, By Platform - 2024 to 2034
Fig 41: Europe Market Y-o-Y Growth Projections, By Platform - 2024 to 2034
Fig 42: Europe Market Attractiveness Index, By Platform - 2024 to 2034
Fig 43: Europe Market Share, By Application - 2024 to 2034
Fig 44: Europe Market Y-o-Y Growth Projections, By Application - 2024 to 2034
Fig 45: Europe Market Attractiveness Index, By Application - 2024 to 2034
Fig 46: Europe Market Share, By Therapeutic Area - 2024 to 2034
Fig 47: Europe Market Y-o-Y Growth Projections, By Therapeutic Area - 2024 to 2034
Fig 48: Europe Market Attractiveness Index, By Therapeutic Area - 2024 to 2034
Fig 49: Europe Market Share, By Country - 2024 to 2034
Fig 50: Europe Market Y-o-Y Growth Projections, By Country - 2024 to 2034
Fig 51: Europe Market Attractiveness Index, By Country - 2024 to 2034
Fig 52: Y-o-Y Growth Comparison of Market: East Asia Vs East Asia Countries Vs East Asia Average
Fig 53: East Asia Market Share, By Product - 2024 to 2034
Fig 54: East Asia Market Y-o-Y Growth Projections, By Product - 2024 to 2034
Fig 55: East Asia Market Attractiveness Index, By Product - 2024 to 2034
Fig 56: East Asia Market Share, By Platform - 2024 to 2034
Fig 57: East Asia Market Y-o-Y Growth Projections, By Platform - 2024 to 2034
Fig 58: East Asia Market Attractiveness Index, By Platform - 2024 to 2034
Fig 59: East Asia Market Share, By Application - 2024 to 2034
Fig 60: East Asia Market Y-o-Y Growth Projections, By Application - 2024 to 2034
Fig 61: East Asia Market Attractiveness Index, By Application - 2024 to 2034
Fig 62: East Asia Market Share, By Therapeutic Area - 2024 to 2034
Fig 63: East Asia Market Y-o-Y Growth Projections, By Therapeutic Area - 2024 to 2034
Fig 64: East Asia Market Attractiveness Index, By Therapeutic Area - 2024 to 2034
Fig 65: East Asia Market Share, By Country - 2024 to 2034
Fig 66: East Asia Market Y-o-Y Growth Projections, By Country - 2024 to 2034
Fig 67: East Asia Market Attractiveness Index, By Country - 2024 to 2034
Fig 68: Y-o-Y Growth Comparison of Market: South Asia Vs South Asia Countries Vs South Asia Average
Fig 69: South Asia Market Share, By Product - 2024 to 2034
Fig 70: South Asia Market Y-o-Y Growth Projections, By Product - 2024 to 2034
Fig 71: South Asia Market Attractiveness Index, By Product - 2024 to 2034
Fig 72: South Asia Market Share, By Platform - 2024 to 2034
Fig 73: South Asia Market Y-o-Y Growth Projections, By Platform - 2024 to 2034
Fig 74: South Asia Market Attractiveness Index, By Platform - 2024 to 2034
Fig 75: South Asia Market Share, By Application - 2024 to 2034
Fig 76: South Asia Market Y-o-Y Growth Projections, By Application - 2024 to 2034
Fig 77: South Asia Market Attractiveness Index, By Application - 2024 to 2034
Fig 78: South Asia Market Share, By Therapeutic Area - 2024 to 2034
Fig 78: South Asia Market Y-o-Y Growth Projections, By Therapeutic Area - 2024 to 2034
Fig 80: South Asia Market Attractiveness Index, By Therapeutic Area - 2024 to 2034
Fig 81: South Asia Market Share, By Country - 2024 to 2034
Fig 82: South Asia Market Y-o-Y Growth Projections, By Country - 2024 to 2034
Fig 83: South Asia Market Attractiveness Index, By Country - 2024 to 2034
Fig 84: Y-o-Y Growth Comparison of Market: Latin America Vs Latin America Countries Vs Latin America Average
Fig 85: Latin America Market Share, By Product - 2024 to 2034
Fig 86: Latin America Market Y-o-Y Growth Projections, By Product - 2024 to 2034
Fig 87: Latin America Market Attractiveness Index, By Product - 2024 to 2034
Fig 88: Latin America Market Share, By Platform - 2024 to 2034
Fig 89: Latin America Market Y-o-Y Growth Projections, By Platform - 2024 to 2034
Fig 90: Latin America Market Attractiveness Index, By Platform - 2024 to 2034
Fig 91: Latin America Market Share, By Application - 2024 to 2034
Fig 92: Latin America Market Y-o-Y Growth Projections, By Application - 2024 to 2034
Fig 93: Latin America Market Attractiveness Index, By Application - 2024 to 2034
Fig 94: Latin America Market Share, By Therapeutic Area - 2024 to 2034
Fig 95: Latin America Market Y-o-Y Growth Projections, By Therapeutic Area - 2024 to 2034
Fig 96: Latin America Market Attractiveness Index, By Therapeutic Area - 2024 to 2034
Fig 97: Latin America Market Share, By Country - 2024 to 2034
Fig 98: Latin America Market Y-o-Y Growth Projections, By Country - 2024 to 2034
Fig 99: Latin America Market Attractiveness Index, By Country - 2024 to 2034
Fig 100: Y-o-Y Growth Comparison of Market: MEA Vs MEA Countries Vs MEA Average
Fig 101: MEA Market Share, By Product - 2024 to 2034
Fig 102: MEA Market Y-o-Y Growth Projections, By Product - 2024 to 2034
Fig 103: MEA Market Attractiveness Index, By Product - 2024 to 2034
Fig 104: MEA Market Share, By Platform - 2024 to 2034
Fig 105: MEA Market Y-o-Y Growth Projections, By Platform - 2024 to 2034
Fig 106: MEA Market Attractiveness Index, By Platform - 2024 to 2034
Fig 107: MEA Market Share, By Application - 2024 to 2034
Fig 108: MEA Market Y-o-Y Growth Projections, By Application - 2024 to 2034
Fig 109: MEA Market Attractiveness Index, By Application - 2024 to 2034
Fig 110: MEA Market Share, By Therapeutic Area - 2024 to 2034
Fig 111: MEA Market Y-o-Y Growth Projections, By Therapeutic Area - 2024 to 2034
Fig 112: MEA Market Attractiveness Index, By Therapeutic Area - 2024 to 2034
Fig 113: MEA Market Share, By Country - 2024 to 2034
Fig 114: MEA Market Y-o-Y Growth Projections, By Country - 2024 to 2034
Fig 115: MEA Market Attractiveness Index, By Country - 2024 to 2034
Fig 116: Y-o-Y Growth Comparison of Market: Oceania Vs Oceania Countries Vs Oceania Average
Fig 117: Oceania Market Share, By Product - 2024 to 2034
Fig 118: Oceania Market Y-o-Y Growth Projections, By Product - 2024 to 2034
Fig 119: Oceania Market Attractiveness Index, By Product - 2024 to 2034
Fig 120: Oceania Market Share, By Platform - 2024 to 2034
Fig 121: Oceania Market Y-o-Y Growth Projections, By Platform - 2024 to 2034
Fig 122: Oceania Market Attractiveness Index, By Platform - 2024 to 2034
Fig 123: Oceania Market Share, By Application - 2024 to 2034
Fig 124: Oceania Market Y-o-Y Growth Projections, By Application - 2024 to 2034
Fig 125: Oceania Market Attractiveness Index, By Application - 2024 to 2034
Fig 126: Oceania Market Share, By Therapeutic Area - 2024 to 2034
Fig 127: Oceania Market Y-o-Y Growth Projections, By Therapeutic Area - 2024 to 2034
Fig 128: Oceania Market Attractiveness Index, By Therapeutic Area - 2024 to 2034
Fig 129: Oceania Market Share, By Country - 2024 to 2034
Fig 130: Oceania Market Y-o-Y Growth Projections, By Country - 2024 to 2034
Fig 131: Oceania Market Attractiveness Index, By Country - 2024 to 2034
Fig 132: United States Market share by Product, 2023
Fig 133: United States Market share by Platform, 2023
Fig 134: United States Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 135: United States Market Share by Therapeutic Area, 2023
Fig 136: Canada Market share by Product, 2023
Fig 137: Canada Market share by Platform, 2023
Fig 138: Canada Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 139: Canada Market Share by Therapeutic Area, 2023
Fig 140: Germany Market share by Product, 2023
Fig 141: Germany Market share by Platform, 2023
Fig 142: Germany Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 143: Germany Market Share by Therapeutic Area, 2023
Fig 144: United Kingdom Market share by Product, 2023
Fig 145: United Kingdom Market share by Platform, 2023
Fig 146: United Kingdom Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 147: United Kingdom Market Share by Therapeutic Area, 2023
Fig 148: France Market share by Product, 2023
Fig 149: France Market share by Platform, 2023
Fig 150: France Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 151: France Market Share by Therapeutic Area, 2023
Fig 152: Russia Market share by Product, 2023
Fig 153: Russia Market share by Platform, 2023
Fig 154: Russia Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 155: Russia Market Share by Therapeutic Area, 2023
Fig 156: Spain Market share by Product, 2023
Fig 157: Spain Market share by Platform, 2023
Fig 158: Spain Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 159: Spain Market Share by Therapeutic Area, 2023
Fig 160: Italy Market share by Product, 2023
Fig 161: Italy Market share by Platform, 2023
Fig 162: Italy Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 163: Italy Market Share by Therapeutic Area, 2023
Fig 164: China Market share by Product, 2023
Fig 165: China Market share by Platform, 2023
Fig 166: China Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 167: China Market Share by Therapeutic Area, 2023
Fig 168: Japan Market share by Product, 2023
Fig 169: Japan Market share by Platform, 2023
Fig 170: Japan Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 171: Japan Market Share by Therapeutic Area, 2023
Fig 172: South Korea Market share by Product, 2023
Fig 173: South Korea Market share by Platform, 2023
Fig 174: South Korea Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 175: South Korea Market Share by Therapeutic Area, 2023
Fig 176: India Market share by Product, 2023
Fig 177: India Market share by Platform, 2023
Fig 178: India Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 179: India Market Share by Therapeutic Area, 2023
Fig 180: Singapore Market share by Product, 2023
Fig 181: Singapore Market share by Platform, 2023
Fig 182: Singapore Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 183: Singapore Market Share by Therapeutic Area, 2023
Fig 184: Indonesia Market share by Product, 2023
Fig 185: Indonesia Market share by Platform, 2023
Fig 186: Indonesia Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 187: Indonesia Market Share by Therapeutic Area, 2023
Fig 188: Thailand Market share by Product, 2023
Fig 189: Thailand Market share by Platform, 2023
Fig 190: Thailand Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 191: Thailand Market Share by Therapeutic Area, 2023
Fig 192: Brazil Market share by Product, 2023
Fig 193: Brazil Market share by Platform, 2023
Fig 194: Brazil Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 195: Brazil Market Share by Therapeutic Area, 2023
Fig 196: Mexico Market share by Product, 2023
Fig 197: Mexico Market share by Platform, 2023
Fig 198: Mexico Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 199: Mexico Market Share by Therapeutic Area, 2023
Fig 200: Turkey Market share by Product, 2023
Fig 201: Turkey Market share by Platform, 2023
Fig 202: Turkey Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 203: Turkey Market Share by Therapeutic Area, 2023
Fig 204: GCC Countries Market share by Product, 2023
Fig 205: GCC Countries Market share by Platform, 2023
Fig 206: GCC Countries Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 207: GCC Countries Market Share by Therapeutic Area, 2023
Fig 208: South Africa Market share by Product, 2023
Fig 209: South Africa Market share by Platform, 2023
Fig 210: South Africa Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 211: South Africa Market Share by Therapeutic Area, 2023
Fig 212: Australia Market share by Product, 2023
Fig 213: Australia Market share by Platform, 2023
Fig 214: Australia Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 215: Australia Market Share by Therapeutic Area, 2023
Fig 216: New Zealand Market share by Product, 2023
Fig 217: New Zealand Market share by Platform, 2023
Fig 218: New Zealand Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 219: New Zealand Market Share by Therapeutic Area, 2023
- Frequently Asked Questions -
How big is the size of the biologics contract manufacturing market?
The global biologics contract manufacturing market is pegged at US$ 21.19 billion in 2024.
What is the demand projection for biologics contract manufacturing for 2034?
Demand for biologics contract manufacturing services is predicted to reach a market value of US$ 51.81 billion by 2024.
What is the projected growth rate for the global market?
The global market is forecasted to expand at 9.4% CAGR from 2024 to 2034.
What is the demand outlook for mammalian-based biologics contract manufacturing services?
Demand for mammalian-based biologics contract manufacturing is projected to increase at 9.7% CAGR and reach a value of US$ 39.27 billion by 2034-end.
At what rate is the United States market foreseen to expand?
The market in the United States is predicted to advance at 9.6% CAGR from 2024 to 2034.
What is the demand projection for biologics contract manufacturing facilities in oncology?
Demand for biologics contract manufacturing in oncology is projected to reach a market value of US$ 12.3 billion by the end of 2034.
Related Reports
Biologics Contract Manufacturing Market